0001127602-16-044742.txt : 20160303 0001127602-16-044742.hdr.sgml : 20160303 20160303145413 ACCESSION NUMBER: 0001127602-16-044742 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160301 FILED AS OF DATE: 20160303 DATE AS OF CHANGE: 20160303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES INC CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MILLIGAN JOHN F CENTRAL INDEX KEY: 0001191589 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 161480680 MAIL ADDRESS: STREET 1: C/O GILEAD SCIENCES, INC. STREET 2: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2016-03-01 0000882095 GILEAD SCIENCES INC GILD 0001191589 MILLIGAN JOHN F GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 1 1 President, COO and Director Common Stock 2016-03-01 4 M 0 112000 16.395 A 1170963 D Common Stock 2016-03-01 4 S 0 112000 87.7946 D 1058963 D Non-qualified Stock Option (Right to Buy) 16.395 2016-03-01 4 M 0 112000 0 D 2017-01-22 Common Stock 112000 448000 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Sale prices reported for the transactions reported here range from $87.31 to $88.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. /s/ Brett A. Pletcher by Power of Attorney for John F. Milligan 2016-03-03